Wednesday, July 8, 2026

Patent intelligence · US

US 7368435

Topical endoparasiticide and ectoparasiticide formulations

granted A61PA61P33/00A61P33/10A61P33/14
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 2
Applicant portfolio 20
Patent details — US 7368435
Jurisdiction
US
Status
granted
Grant date
May 6, 2008
Expiration
May 1, 2028
Claims
10
CPC classes
A61P, A61P33/00, A61P33/10, A61P33/14
View on Google Patents ↗

Quick answer

US 7368435 (Topical endoparasiticide and ectoparasiticide formulations) is held by Summit VetPharm, LLC. Status: granted. Granted May 6, 2008. Expires May 1, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61P, A61P33/00, A61P33/10, A61P33/14

More from Summit VetPharm, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12318487

    Solid tablet dosage form of ridinilazole

    SUMMIT (OXFORD) LIMITED · Expires May 29, 2045

    granted
  2. US 11344575

    Vascular calcification prevention and treatment

    Summit Innovation Labs LLC · Expires May 26, 2042

    granted
  3. US 11007171

    Treatment and prevention of joint disorders

    Summit Innovation Labs LLC · Expires May 13, 2041

    granted
  4. US 9763925

    Antibacterial compounds

    SUMMIT THERAPEUTICS PLC · Expires Sep 14, 2037

    granted
  5. US 9492433

    Pharmaceutical composition for the treatment of Duchenne muscular dystrophy

    Summit Corporation Plc · Expires Nov 10, 2036

    granted
  6. US 9314456

    Antibacterial compounds

    SUMMIT THERAPEUTICS PLC · Expires Apr 14, 2036

    granted
  7. US 9278091

    Compounds for the treatment of Clostridium difficile associated disease

    SUMMIT THERAPEUTICS PLC · Expires Mar 3, 2036

    granted
  8. US 8987308

    Compounds for the treatment of Clostridium difficile-associated disease

    Summit Corporation Plc · Expires Mar 19, 2035

    granted

Frequently asked questions

What is US patent 7368435?

US 7368435 (Topical endoparasiticide and ectoparasiticide formulations) is held by Summit VetPharm, LLC. Status: granted. Granted May 6, 2008. Expires May 1, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7368435?

Summit VetPharm, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.

When does US 7368435 expire?

Our index shows an expiration date of May 1, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.